文献速递临床试验与 GCP

氯噻酮与氢氯噻嗪联合阿米洛利不同剂量对原发性高血压血压疗效的析因随机对照试验方案

Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial.
PubMed 文献 · Trials · 2019-12-16

本方案为2×2析因随机双盲临床试验,比较氯噻酮25 mg/日或氢氯噻嗪50 mg/日联合阿米洛利10 mg/日或20 mg/日对原发性高血压患者的降压疗效。主要结局为24小时动态血压监测的收缩压和舒张压较基线平均变化,计划随机84例,随访12周。

要点

  • 比较氯噻酮与氢氯噻嗪联合不同剂量阿米洛利的降压疗效与安全性。
  • 主要结局为24小时动态血压收缩压和舒张压较基线变化。
  • 计划随机84例原发性高血压患者,随访12周。

核心结论

  • 该试验将评估氯噻酮或氢氯噻嗪联合阿米洛利不同剂量对原发性高血压患者的降压疗效与安全性。

研究设计与样本

  • 2×2析因随机双盲临床试验,比较氯噻酮25 mg/日或氢氯噻嗪50 mg/日联合阿米洛利10 mg/日或20 mg/日。
  • 计划随机84例原发性高血压患者,随访12周。

关键数值与推荐

  • 主要结局为24小时动态血压监测的收缩压和舒张压较基线平均变化。
  • 样本量按P alpha 0.05、把握度80%、收缩压标准差9 mmHg、绝对差异6 mmHg计算需76例,增加10%后为84例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thiazide diuretics have demonstrated favorable blood pressure lowering efficacy, but the equivalent doses of their more common agents, chlorthalidone and hydrochlorothiazide, are still unclear. Further, concerns exist regarding adverse metabolic effects, which may be attenuated with the concomitant administration of a potassium-sparing diuretic, such as amiloride. This trial aims to investigate the efficacy of chlorthalidone and hydrochlorothiazide, in combination with amiloride at different doses, for initial management of patients with primary hypertension. METHODS/DESIGN: This is a factorial (2 × 2) randomized double-blinded clinical trial comparing the association of a thiazide diuretic (chlorthalidone 25 mg/day or hydrochlorothiazide 50 mg/day) with a potassium-sparing diuretic (amiloride 10 mg/day or amiloride 20 mg/day) in patients with primary hypertension. The primary outcome will be the mean change from baseline in 24-h systolic and diastolic blood pressure measured by ambulatory blood pressure monitoring. The secondary outcomes will be the mean change from baseline in daytime and nighttime systolic and diastolic blood pressure measured by ambulatory blood pressure monitoring, mean change from baseline in systolic and diastolic blood pressure measured by office blood pressure, incidence of adverse events, variation of laboratory parameters, and proportion of patients who achieved blood pressure control. The follow-up will last 12 weeks. For a P alpha of 0.05, power of 80%, standard deviation of 9 mmHg, and absolute difference of 6 mmHg on systolic blood pressure on 24-h ambulatory blood pressure monitoring, it will be necessary to study a total of 76 patients. The sample size will be increased by 10% to compensate for losses, resulting in 84 patients being randomized. DISCUSSION: Diuretics are pivotal drugs for the treatment of hypertension. Chlorthalidone and hydrochlorothiazide, in combination with amiloride in multiple doses, will be tested in terms of blood pressure lowering efficacy and safety. Since the intensity of blood pressure reduction is the major determinant of reduction in cardiovascular risk in hypertensive patients, this study will help to determine which combination of diuretics represents the most appropriate treatment for this population. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03928145. Registered on 25 April 2019. Last update on 29 April 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Martins VM, Helal L, Ferrari F, et al. Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial. Trials. 2019. PMID: 31843024. doi:10.1186/s13063-019-3909-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。